[{"id":"9480eee5-c88d-4aa5-a04a-bfe171590b90","acronym":"INCB 84344-102","url":"https://clinicaltrials.gov/study/NCT03934372","created_at":"2021-01-18T19:22:38.750Z","updated_at":"2025-02-25T14:40:12.243Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors","source_id_and_acronym":"NCT03934372 - INCB 84344-102","lead_sponsor":"Incyte Biosciences International Sàrl","biomarkers":" FLT3 • ABL1 • BCR • RET • FGFR • BLM","pipe":" | ","alterations":" EGFR mutation • KIT mutation • FGFR mutation • RET mutation","tags":["FLT3 • ABL1 • BCR • RET • FGFR • BLM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • KIT mutation • FGFR mutation • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/29/2020","start_date":" 01/29/2020","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-14"},{"id":"d1bc1259-71d0-45e4-a4ce-99f4232d61c4","acronym":"AZURE","url":"https://clinicaltrials.gov/study/NCT05609942","created_at":"2023-04-03T15:02:58.943Z","updated_at":"2025-02-25T14:41:39.851Z","phase":"Phase 1","brief_title":"Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies","source_id_and_acronym":"NCT05609942 - AZURE","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA D842V • PDGFRA mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA D842V • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • elenestinib (BLU-263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":" Primary completion: 01/14/2025","primary_completion_date":" 01/14/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-14"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"7ae66fef-a243-4d8f-b364-a73eb3507cdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04633122","created_at":"2021-01-19T20:36:54.322Z","updated_at":"2025-02-25T15:34:48.949Z","phase":"Phase 2","brief_title":"A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib","source_id_and_acronym":"NCT04633122","lead_sponsor":"Zai Lab (Shanghai) Co., Ltd.","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA mutation","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • Qinlock (ripretinib)"],"overall_status":"Completed","enrollment":" Enrollment 108","initiation":"Initiation: 11/25/2020","start_date":" 11/25/2020","primary_txt":" Primary completion: 07/20/2022","primary_completion_date":" 07/20/2022","study_txt":" Completion: 07/20/2022","study_completion_date":" 07/20/2022","last_update_posted":"2025-02-10"},{"id":"b25768d2-e63d-4ef1-89e9-0d4fc5455a84","acronym":"StrateGIST 1","url":"https://clinicaltrials.gov/study/NCT05489237","created_at":"2022-08-05T13:57:06.723Z","updated_at":"2025-02-25T13:13:05.882Z","phase":"Phase 1","brief_title":"First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors","source_id_and_acronym":"NCT05489237 - StrateGIST 1","lead_sponsor":"IDRx, Inc.","biomarkers":" PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA mutation • PDGFRA exon 18 mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA mutation • PDGFRA exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • velzatinib (GSK6042981)"],"overall_status":"Recruiting","enrollment":" Enrollment 269","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 04/24/2026","primary_completion_date":" 04/24/2026","study_txt":" Completion: 09/13/2026","study_completion_date":" 09/13/2026","last_update_posted":"2025-01-17"},{"id":"ddcdaa98-710f-4836-a6b4-89e5e80022ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT05957367","created_at":"2023-07-24T15:08:40.775Z","updated_at":"2024-07-02T16:34:59.920Z","phase":"Phase 1/2","brief_title":"A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies","source_id_and_acronym":"NCT05957367","lead_sponsor":"Deciphera Pharmaceuticals LLC","biomarkers":" BRAF • KIT • PDGFRA","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • KIT mutation • KIT exon 11 mutation • PDGFRA mutation","tags":["BRAF • KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • KIT mutation • KIT exon 11 mutation • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Braftovi (encorafenib) • Qinlock (ripretinib) • inlexisertib (DCC-3116)"],"overall_status":"Recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 09/28/2023","start_date":" 09/28/2023","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-05-31"},{"id":"9f4d4138-2575-46b3-8cf6-894603dcfc63","acronym":"","url":"https://clinicaltrials.gov/study/NCT04908176","created_at":"2021-06-01T17:53:25.780Z","updated_at":"2024-07-02T16:35:07.927Z","phase":"Phase 1","brief_title":"A Drug-drug Interaction Study of Avapritinib and Midazolam","source_id_and_acronym":"NCT04908176","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib) • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 08/24/2022","start_date":" 08/24/2022","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 04/12/2024","study_completion_date":" 04/12/2024","last_update_posted":"2024-04-23"},{"id":"46bd478e-b8d0-4e9c-a5fd-b1d6d75d3215","acronym":"","url":"https://clinicaltrials.gov/study/NCT02975700","created_at":"2021-01-18T14:37:44.830Z","updated_at":"2024-07-02T16:35:10.337Z","phase":"","brief_title":"A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma","source_id_and_acronym":"NCT02975700","lead_sponsor":"Daiichi Sankyo Co., Ltd.","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Turalio (pexidartinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 01/31/2017","start_date":" 01/31/2017","primary_txt":" Primary completion: 08/31/2018","primary_completion_date":" 08/31/2018","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-04-10"},{"id":"f0120f59-10df-43f7-b5bb-987a4f3afad2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05493215","created_at":"2022-08-09T17:04:45.434Z","updated_at":"2024-07-02T16:35:12.164Z","phase":"Phase 2","brief_title":"Imatinib TDM in GIST","source_id_and_acronym":"NCT05493215","lead_sponsor":"Reema A. Patel","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA D842V • PDGFRA mutation","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA D842V • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 03/26/2024","start_date":" 03/26/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-01"},{"id":"0a617e4d-d65e-4f5c-a559-adf45a31c05c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01738139","created_at":"2021-01-18T07:36:17.833Z","updated_at":"2024-07-02T16:35:13.511Z","phase":"Phase 1","brief_title":"Ipilimumab and Imatinib Mesylate in Advanced Cancer","source_id_and_acronym":"NCT01738139","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation • KIT positive","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • imatinib"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 02/19/2013","start_date":" 02/19/2013","primary_txt":" Primary completion: 12/13/2022","primary_completion_date":" 12/13/2022","study_txt":" Completion: 12/13/2023","study_completion_date":" 12/13/2023","last_update_posted":"2024-03-21"},{"id":"afe5eda5-b0b2-4528-9023-e2c1d7118027","acronym":"","url":"https://clinicaltrials.gov/study/NCT05905887","created_at":"2023-06-15T17:08:41.962Z","updated_at":"2024-07-02T16:35:17.151Z","phase":"Phase 2","brief_title":"Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor","source_id_and_acronym":"NCT05905887","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • imatinib • sunitinib • AiTan (rivoceranib) • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 09/06/2023","start_date":" 09/06/2023","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-02-28"},{"id":"0eefbaf9-a4ea-454b-868c-1b99280a8dd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01541709","created_at":"2021-01-18T06:30:56.005Z","updated_at":"2024-07-02T16:35:24.757Z","phase":"Phase 2","brief_title":"Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI","source_id_and_acronym":"NCT01541709","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • ANO1","pipe":" | ","alterations":" KIT mutation • KIT exon 9 mutation","tags":["KIT • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 9 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-01-01"},{"id":"4c2f1c18-6e61-4a09-9dd2-0ccca96142b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03944304","created_at":"2021-01-18T19:25:15.034Z","updated_at":"2024-07-02T16:35:24.855Z","phase":"Phase 2","brief_title":"Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.","source_id_and_acronym":"NCT03944304","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • imatinib • sunitinib • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/27/2019","start_date":" 05/27/2019","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-01-01"},{"id":"bf439f30-e0dc-43f8-a4c4-f4b1f0fa3a26","acronym":"","url":"https://clinicaltrials.gov/study/NCT02571036","created_at":"2021-01-17T17:36:28.986Z","updated_at":"2024-07-02T16:35:26.428Z","phase":"Phase 1","brief_title":"A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies","source_id_and_acronym":"NCT02571036","lead_sponsor":"Deciphera Pharmaceuticals LLC","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA mutation • KIT amplification","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA mutation • KIT amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qinlock (ripretinib)"],"overall_status":"Completed","enrollment":" Enrollment 282","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 04/29/2022","primary_completion_date":" 04/29/2022","study_txt":" Completion: 04/29/2022","study_completion_date":" 04/29/2022","last_update_posted":"2023-12-13"},{"id":"ff971a31-4620-40ce-aa35-33a25eb28431","acronym":"","url":"https://clinicaltrials.gov/study/NCT02413736","created_at":"2021-01-18T11:31:48.616Z","updated_at":"2024-07-02T16:35:29.677Z","phase":"Phase 3","brief_title":"Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST","source_id_and_acronym":"NCT02413736","lead_sponsor":"Heikki Joensuu","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation • PDGFRA mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 255","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2033","study_completion_date":" 05/01/2033","last_update_posted":"2023-11-09"},{"id":"e83462de-87f7-4dab-90df-3962b5abd242","acronym":"","url":"https://clinicaltrials.gov/study/NCT01823198","created_at":"2021-01-18T08:06:03.874Z","updated_at":"2024-07-02T16:35:30.156Z","phase":"Phase 1/2","brief_title":"Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies","source_id_and_acronym":"NCT01823198","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • DNMT3A • TET2","pipe":" | ","alterations":" FLT3 mutation • KIT mutation • DNMT3A mutation • TET2 mutation","tags":["FLT3 • DNMT3A • TET2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • KIT mutation • DNMT3A mutation • TET2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • Proleukin (aldesleukin) • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 06/11/2013","start_date":" 06/11/2013","primary_txt":" Primary completion: 05/10/2022","primary_completion_date":" 05/10/2022","study_txt":" Completion: 05/10/2022","study_completion_date":" 05/10/2022","last_update_posted":"2023-11-07"},{"id":"01427b63-46d6-491c-9cbc-db1659ee55e6","acronym":"","url":"https://clinicaltrials.gov/study/NCT06116318","created_at":"2023-11-03T20:12:27.754Z","updated_at":"2024-07-02T16:35:30.497Z","phase":"","brief_title":"A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia","source_id_and_acronym":"NCT06116318","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2023-11-03"},{"id":"2ec35ef1-8428-4bae-b84d-89bca1d8d7d1","acronym":"ELEGANT","url":"https://clinicaltrials.gov/study/NCT05737849","created_at":"2023-02-21T15:01:31.906Z","updated_at":"2024-07-02T16:35:32.098Z","phase":"","brief_title":"A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer in China (ELEGANT)","source_id_and_acronym":"NCT05737849 - ELEGANT","lead_sponsor":"Takeda","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR wild-type • KIT mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR wild-type • KIT mutation"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/30/2024","start_date":" 01/30/2024","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-10-23"},{"id":"9029b63b-49b7-4f5b-bf2d-d1dd5f6be242","acronym":"","url":"https://clinicaltrials.gov/study/NCT04006769","created_at":"2021-01-18T19:41:21.824Z","updated_at":"2024-07-02T16:35:32.887Z","phase":"Phase 1","brief_title":"Entacapone Combination With Imatinib for Treatment of GIST","source_id_and_acronym":"NCT04006769","lead_sponsor":"Xiangya Hospital of Central South University","biomarkers":" KIT • FTO","pipe":" | ","alterations":" KIT mutation • KIT expression • FTO expression","tags":["KIT • FTO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT expression • FTO expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 10/30/2020","start_date":" 10/30/2020","primary_txt":" Primary completion: 08/31/2022","primary_completion_date":" 08/31/2022","study_txt":" Completion: 08/31/2022","study_completion_date":" 08/31/2022","last_update_posted":"2023-10-18"},{"id":"94486af4-814e-42b0-b6a1-5049f540ec18","acronym":"IMPAKT","url":"https://clinicaltrials.gov/study/NCT04546074","created_at":"2021-01-18T21:44:39.179Z","updated_at":"2025-02-25T16:10:36.563Z","phase":"Phase 1/2","brief_title":"Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma","source_id_and_acronym":"NCT04546074 - IMPAKT","lead_sponsor":"Keio University","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • imatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 09/14/2020","start_date":" 09/14/2020","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2023-10-03"},{"id":"1d571185-66c3-4224-a385-8f3e4c2f1022","acronym":"PATHFINDER","url":"https://clinicaltrials.gov/study/NCT03580655","created_at":"2021-01-18T17:36:58.229Z","updated_at":"2024-07-02T16:35:41.207Z","phase":"Phase 2","brief_title":"(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis","source_id_and_acronym":"NCT03580655 - PATHFINDER","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" TMB • KIT","pipe":" | ","alterations":" KIT mutation • KIT D816V","tags":["TMB • KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT D816V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 11/21/2018","start_date":" 11/21/2018","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2023-08-02"},{"id":"b1c70258-d4b2-41c1-b83d-b1d3967088dd","acronym":"PIRKER","url":"https://clinicaltrials.gov/study/NCT05970900","created_at":"2023-08-01T15:10:17.424Z","updated_at":"2024-07-02T16:35:41.348Z","phase":"Phase 3","brief_title":"Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST","source_id_and_acronym":"NCT05970900 - PIRKER","lead_sponsor":"Fujian Medical University Union Hospital","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2029","study_completion_date":" 10/01/2029","last_update_posted":"2023-08-01"},{"id":"2b362821-228e-4647-ab9a-04854ffc8751","acronym":"","url":"https://clinicaltrials.gov/study/NCT05381753","created_at":"2022-05-19T12:57:08.164Z","updated_at":"2024-07-02T16:35:43.571Z","phase":"","brief_title":"Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World","source_id_and_acronym":"NCT05381753","lead_sponsor":"CStone Pharmaceuticals","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • Ayvakit (avapritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 08/29/2022","start_date":" 08/29/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-07-10"},{"id":"b23fd882-ff28-4564-bc15-fe532fcc31ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT00700882","created_at":"2021-01-17T17:21:43.588Z","updated_at":"2024-07-02T16:35:44.187Z","phase":"Phase 2","brief_title":"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery","source_id_and_acronym":"NCT00700882","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation • KIT positive • KIT amplification","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT positive • KIT amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 81","initiation":"Initiation: 07/02/2009","start_date":" 07/02/2009","primary_txt":" Primary completion: 05/06/2016","primary_completion_date":" 05/06/2016","study_txt":" Completion: 12/28/2020","study_completion_date":" 12/28/2020","last_update_posted":"2023-06-30"}]